Scientists develop DNA-delivered immunotherapy that targets ovarian cancer more effectively

MedicalXpress | Jul 19, 2026

Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies. It's a major development for this type of immunotherapy, which has been used successfully against blood cancers but has so far been less effective in solid tumors.